Pfizer Inc. (PFE) Stock Rating Upgraded by Barclays PLC
Pfizer Inc. (NYSE:PFE) was upgraded by equities research analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating in a research note issued on Tuesday, The Fly reports.
PFE has been the subject of several other reports. Jefferies Group set a $40.00 target price on Pfizer and gave the company a “buy” rating in a report on Monday, August 1st. Sanford C. Bernstein set a $38.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, August 2nd. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.08 target price for the company in a report on Tuesday, August 2nd. Citigroup Inc. restated a “neutral” rating and set a $37.00 target price on shares of Pfizer in a report on Wednesday, August 3rd. Finally, JPMorgan Chase & Co. set a $40.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, August 3rd. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $37.73.
Shares of Pfizer (NYSE:PFE) opened at 31.54 on Tuesday. The company has a market cap of $191.40 billion, a P/E ratio of 31.67 and a beta of 0.90. Pfizer has a 12-month low of $28.25 and a 12-month high of $37.39. The stock’s 50 day moving average price is $31.95 and its 200 day moving average price is $34.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.62 by $0.01. The firm had revenue of $13.05 billion for the quarter, compared to the consensus estimate of $13.05 billion. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. Pfizer’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 earnings per share. On average, analysts forecast that Pfizer will post $2.41 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.80%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is 106.20%.
In other news, insider Anthony J. Maddaluna sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total value of $330,000.00. Following the transaction, the insider now directly owns 112,087 shares in the company, valued at approximately $3,698,871. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Albert Bourla sold 18,390 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $30.05, for a total value of $552,619.50. Following the completion of the transaction, the insider now owns 149,199 shares in the company, valued at $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in PFE. Nelson Roberts Investment Advisors LLC increased its position in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC purchased a new position in Pfizer during the second quarter worth about $110,000. First National Bank Sioux Falls increased its position in Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,750 shares during the period. Tuttle Tactical Management LLC purchased a new position in Pfizer during the second quarter worth about $117,000. Finally, Cornerstone Advisors Inc. increased its position in Pfizer by 17.4% in the third quarter. Cornerstone Advisors Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 541 shares during the period. Hedge funds and other institutional investors own 68.53% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.